CorMedix Completes Sale of $5.4 Million of NOL Tax Benefits Through New Jersey Economic Development Authority Program

NEXT STORY
Allena Pharmaceuticals Appoints Allene Diaz to its Board of Directors
PREV STORY
Intensity Therapeutics Receives Fast Track Designation from U.S. FDA for Development of INT230-6 as Treatment for Relapsed or Metastatic Triple Negative Breast Cancer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Ascendis Pharma A/S Invites the Public to Attend “A Story of Courage: Living with Hypoparathyroidism” in Support of World Hypopara Awareness Day on June 1, 2021

author_avatar
NASDAQ Market News

BioAegis Therapeutics Announces Publication of a Compassionate Use Case Study of a Critical COVID-19 Patient

author_avatar
NASDAQ Market News

MRM Health Announces First Patient Dosed with Next Generation Live Microbiome Consortia Therapeutic MH002 in Phase 1b/2a Study in Patients with Ulcerative Colitis

author_avatar
NASDAQ Market News